Celecoxib Oral Solution Relieves Migraine Pain and Improves Other Symptoms
Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective and widely used for migraine, but gastrointestinal tolerability and safety limit usage by many patients. In a study, researchers have found that celecoxib oral solution is superior to placebo for pain freedom and freedom from the most bothersome symptom when patients treat a migraine attack of any baseline pain intensity. The study findings were published in the Journal of Pain Research on January 16, 2021.
In a previous 2-period, randomized, controlled study, Dr Sagar Munjal and his team evaluated the effect of DFN-15—an oral, ready-made liquid solution of selective cyclo-oxygenase-2 inhibitor celecoxib and placebo for the acute treatment of a moderate-severe migraine attack. In the first treatment period, they found that DFN-15 was superior to placebo on the co-primary efficacy endpoints of pain freedom and other bothersome symptoms. Therefore, they conducted a second treatment period on the same patients by re-randomization and reported the findings.
In the first treatment period, the researchers included a total of 531 adult patients with at least a 1-year history of migraine, including 2 to 8 attacks and no more than 14 headache days per month. The patients were randomly assigned to double-blind trial treatment of attacks of moderate or severe pain with DFN-15,120 mg or placebo. For this present analysis, the researchers re-randomized the 491 patients to either DFN-15 (n=243) or placebo (n=248) to manage an attack of any baseline pain intensity (mild, moderate, or severe). Co-primary efficacy endpoints specified for the first attack were not specified for the second attack.
Key findings of the study were:
- At baseline, the researchers noted that pain intensity was mild in 17.2% (n=85) of patients, moderate in 58.4% (n=288) of patients, and severe in 22.9% (n=113) of patients.
- After 2 hours post-dose, they found that the DFN-15 was superior to placebo for freedom from pain (46.2% vs 31.1%) and the most bothersome symptom (63.4%vs 50.0%).
- They reported a total of 35 Treatment-emergent adverse events (TEAEs), among which 6.1% is from the DFN-15 group and 8% from the placebo group.
- They noted that the study drug-related TEAEs occurred in 5.1% of patients (DFN-15: 4.5% vs placebo 5.6%). The most common adverse events reported were nausea (1%) and dysgeusia (0.8%).
- They reported no serious TEAEs, severe TEAEs, or TEAEs leading to study drug termination.
The authors concluded, "DFN-15 was significantly superior to placebo on multiple efficacy endpoints, including 2-hour freedom from pain and the MBS, as well as headache relief and functional disability. Safety and tolerability results were predictable and similar to placebo."
For further information:
DOI: https://doi.org/10.2147/JPR.S287571
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.